anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A number of studies have focused on the evaluation of the relationship between pre-pregnancy overweight and polyunsaturated fatty acids content in human milk. However, given the complexity of potentially confounding risk factors, the use of graphical tools is recommended to identify possible biases. This article aims to propose a theoretical model of causality using the directed acyclic graph between pre-pregnancy overweight and polyunsaturated fatty acids content in human milk. Methods: An extensive literature review was performed to identify variables with causal relationships with exposure and/or outcome. The choice of variables for adjustment followed the graphic algorithm that comprises six criteria for selecting a minimum set of potentially confounding variables. Socioeconomic conditions, interpartum interval, maternal age and food consumption pattern were the variables that would have to be adjusted in order to estimate the total effect of pre-pregnancy overweight on polyunsaturated fatty acids content in human milk. The minimum set of variables found in the present study can be used in the analysis of other studies that evaluate this association.
The invention provides a method of preventing or treating cancer in a subject by administering to the subject a therapeutically effective amount of a GPR84 antagonist. Also provided is a method of preventing recurrence of cancer in a subject by administering to the subject a therapeutically effective amount of a GPR84 antagonist. Further, the invention provides a method of modulating the immune system of a subject afflicted with or at risk of cancer by administering to the subject a therapeutically effective amount of a GPR84 antagonist. Still further, the invention provides a method of preventing or treating an inflammatory response in a subject by administering to the subject a therapeutically effective amount of a GPR84 agonist. Also provided is a method of preventing an immune system disease or disorder in a subject by administering to the subject a therapeutically effective amount of a GPR84 agonist. Further, the invention provides a method treating an immune system disease or disorder in a subject by administering to the subject a therapeutically effective amount of a GPR84 agonist. Also, the invention provides a method of modulating the immune system of a subject afflicted with or at risk of an immune system disease or disorder by administering to the subject a therapeutically effective amount of a GPR84 agonist.
Acute kidney injury (AKI) is a common clinical problem, and patients who survive AKI have a high risk of chronic kidney disease (CKD). The acute protective effects of Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors in AKI have been examined, there is still relatively little known regarding the impact of acute CDK4/6 inhibition on the chronic sequence of AKI. Therefore, we utilized the CDK4/6 inhibitor Palbociclib to examine the long-term effects of CDK4/6 inhibition in a rodent model of ischemic AKI. Palbociclib (Palb) was administered during the acute stage or post the acute stage of AKI and mice were sacrificed 21 days post injury. We found that Palb could cause renal senescence and renal fibrosis. Furthermore, dasatinib (D) plus quercetin (Q) were used to eliminate senescent cells in ischemic AKI murine model and Palb was administered post the treatment of D + Q. We found that Palb could reverse the senolytic and antifibrotic effects induced by D + Q, which indicates that the profibrotic effect of Palb could be ascribed to its pro-senescent effects. Our results demonstrate that CDK4/6 inhibitors treatment might be deleterious on the chronic sequence of AKI.
The study relies solely on data from registries and the investigators have taken great care to ensure the validity of these data. Below the main principles and procedures applied are outlined. For the data delivered from the hospital Business Intelligence (BI) database the investigators performed interviews with representatives from each workplace. This was done to ensure that the information about when a workplace underwent the organizational change was accurate, but also what type of organizational change the workplace experienced, how the workplace was organized in terms of departments/wards, and the number of employees at the workplace.The validity of the data supplied by Statistics Denmark relies on the comprehensive procedures to ensure data integrity at Statistics Denmark. All datamanagement by the investigators has been performed in the Stata software package and all decisions are documented in program files (called "do-files" in Stata teminology) to ensure a complete revision trail from the delivered raw data to the dataset used for the final analyses. The investigators have performed extensive data checks, both by tabulations, codebooks, and visual inspection of the data. To ensure against data management errors done by a single investigator when writing the program/do-files, all coding performed in the datamanagement phase has been reviewed by at least one of the other researchers.
Dual trigger: (0.3 mg GnRHa = triptorelin) with + HCG (Choriomon)10 000 IU . will be administered subcutaneously in a single dose 0.3 mg with 10 000 HCG when at least 2 follicles 18 mm in diameter have been observed by ultrasound examination.
FIELD: medicine.SUBSTANCE: invention refers to dermatology and general surgery, and can be used for non-invasive treatment of palmar-plantar warts / spines. For this purpose, silver nitrate is used externally in the form of an officinal preparation "Lapis pencil". Before the therapeutic procedure, the affected skin with a wart/warts is softened by lowering into a soda-salt solution prepared in amount of 1 tablespoon of sodium bicarbonate and 1 tablespoon of sea salt per 1 liter of water at temperature of 43–45 °C. Skin is treated in the affected area and part of healthy skin for 15–20 minutes and dried. If necessary, the scarred tissues are removed with manicure forceps. Thereafter, silver nitrate is continuously applied on the treatment area, first directly on the wart and surrounding tissues and then on the non-infected skin to one centimeter outside along the entire perimeter of the affected area. "Lapis pencil" is moved from the center of the wart to the periphery of the treatment area, spirally from left to right, slightly pressing, reaching the boundary of the treatment area, including directly the wart, surrounding its affected skin tissues and plus up to one centimeter of healthy skin along the entire perimeter of treatment, silver nitrate is applied again on the treatment area, starting from the center of the wart, and so on. At that, around each large wart the entire treatment area will make a circle with diameter of up to 50–60 mm. Around each small wart the entire treatment area will make a circle with diameter of up to 10–20 mm. Treatment procedure for one wart takes 15–20 minutes: up to 10–15 minutes, every wart and affected skin around it is treated, up to 5 minutes, if healthy skin area is 1 cm outside of the affected area. Then the treated skin is air-dried. If necessary, bactericidal adhesive is used. Stage complex procedure of treating affected area and skin is performed once a day in the evening, daily. Therapeutic course is 7 to 15 days. Duration of the course depends on the number of warts/thorns, their diameter and depth of skin involvement. Treatment is performed until tissue recovery is complete.EFFECT: method provides the sparing effect on the aetiological factor of the disease, high immune resistance of the affected region with no recurrences and minimal side effects of the treatment.1 cl, 2 tbl, 30 dwg, 10 ex
<P>PROBLEM TO BE SOLVED: To provide powder regulating pH of the skin surface to weakly acidic, and gentle to the skin.  <P>SOLUTION: There is provided the surface-treated powder regulating the pH of the skin to 3.0-5.0. The power is obtained by treating the surface thereof with a resin having carboxylic acid functional group. Furthermore, the resin having carboxylic acid functional group is preferably polyacrylic acid, polymethacrylic acid, polymaleic acid, or a copolymer of acrylic acid and maleic acid, a copolymer of methacrylic acid and maleic acid, a copolymer of acrylic acid and methacrylic acid, and a copolymer of acrylic acid, methacrylic acid and maleic acid. A cosmetic containing the power is provided, and the cosmetic is particularly preferable as a makeup cosmetic.  <P>COPYRIGHT: (C)2011,JPO&INPIT
Compounds, pharmaceutical compositions including the compounds, and methods of preparation and use thereof are disclosed. The compounds are amide compounds which can be prepared from certain heteroaryl carboxylic acids and certain diazabicycloalkanes. The compounds exhibit selectivity for, and bind with high affinity to, neuronal nicotinic receptors of the α 4 β 2 subtype in the central nervous system (CNS). The compounds and compositions can be used to treat and/or prevent a wide variety of conditions or disorders, particularly CNS disorders. The compounds can: (i) alter the number of nicotinic cholinergic receptors of the brain of the patient, (ii) exhibit neuroprotective effects, and (iii) when employed in effective amounts, not result in appreciable adverse side effects (e.g. side effects such as significant increases in blood pressure and heart rate, significant negative effects upon the gastrointestinal tract, and significant effects upon skeletal muscle).
Hepatocellular carcinoma (HCC) is the predominant form of liver cancer, characterized by high morbidity and mortality rates, as well as unfavorable treatment outcomes. Tripartite motif-containing protein 47 (TRIM47) has been implicated in various diseases including tumor progression with the activity of E3 ubiquitin ligase. However, the precise regulatory mechanisms underlying the involvement of TRIM47 in HCC remain largely unexplored. Here, we provide evidence that TRIM47 exhibits heightened expression in tumor tissues, and its expression is in intimate association with clinical staging and patient prognosis. TRIM47 promotes HCC proliferation, migration, and invasion as an oncogene by in vitro gain- and loss-of-function experiments. TRIM47 knockdown results in HCC ferroptosis induction, primarily through CDO1 involvement to regulate GSH synthesis. Subsequent experiments confirm the interaction between TRIM47 and CDO1 dependent on B30.2 domain, wherein TRIM47 facilitates K48-linked ubiquitination, leading to a decrease in CDO1 protein abundance in HCC. Furthermore, CDO1 is able to counteract the promotional effect of TRIM47 on HCC biological functions. Overall, our research provides novel insight into the mechanism of TRIM47 in CDO1-mediated ferroptosis in HCC cells, highlighting its value as a potential target candidate for HCC therapeutic approaches.
Patients receive induction therapy comprising azacitidine SC QD on days 1-7, mitoxantrone hydrochloride IV over 30 minutes, and etoposide IV over 1 hour on days 4-8. Patients may receive up to 2 additional courses of the same treatment as re-induction or consolidation therapy beginning 35-60 days from the start of the previous course.
PROBLEM TO BE SOLVED: To obtain the subject cosmetic certainly and easily applicable to the whole specified region of the nose in a uniform and tight way without any lateral shift, by having recesses at specific sites of a sheet. SOLUTION: This cosmetic comprises a sheet base 1 and a pack cosmetic 2 impregnated thereinto and held by the sheet base 1. In the above sheet base 1, the surface holding the pack cosmetic 2 is covered with a releasable film 3. The upper edge of the sheet base 1 is made in a gently-sloping mountain-like shape. The sheet base 1 has two recesses 4a and 4b, situated nearer to the centerline, at symmetrical positions with respect to the centerline. Wherein, the two recesses is wedge-shaped and there are slightly oblique cuts so as to gradually approach the centerline to the position corresponding to the upper 1/3 of the longituidnal width (height) of the sheet-like pack cosmetic. The portion sandwiched between the two recesses is made to be a tongue-shaped portion 4c.
Patients in group B underwent anesthesia with bolus of propofol for sedation, and the dosage raged between 0.75 to 1.5 mg/kg to achieve at least OAA/S scale level 3. Dosage of suxamethonium, application of electroconvulsive stimulation, ventilation maneuver, frequency of ECT session, and number of total ECT sessions were same as patients in group T.
BACKGROUND: Cervical cancer (CC) causes more than 311,000 deaths annually worldwide. The integration of human papillomavirus (HPV) is a crucial genetic event that contributes to cervical carcinogenesis. Despite HPV DNA integration is known to disrupt the genomic architecture of both the host and viral genomes in CC, the complexity of this process remains largely unexplored.
RESULTS: In this study, we conducted whole-genome sequencing (WGS) at 55-65X coverage utilizing the PacBio long-read sequencing platform in SiHa and HeLa cells, followed by comprehensive analyses of the sequence data to elucidate the complexity of HPV integration. Firstly, our results demonstrated that PacBio long-read sequencing effectively identifies HPV integration breakpoints with comparable accuracy to targeted-capture Next-generation sequencing (NGS) methods. Secondly, we constructed detailed models of complex integrated genome structures that included both the HPV genome and nearby regions of the human genome by utilizing PacBio long-read WGS. Thirdly, our sequencing results revealed the occurrence of a wide variety of genome-wide structural variations (SVs) in SiHa and HeLa cells. Additionally, our analysis further revealed a potential correlation between changes in gene expression levels and SVs on chromosome 13 in the genome of SiHa cells.
CONCLUSIONS: Using PacBio long-read sequencing, we have successfully constructed complex models illustrating HPV integrated genome structures in SiHa and HeLa cells. This accomplishment serves as a compelling demonstration of the valuable capabilities of long-read sequencing in detecting and characterizing HPV genomic integration structures within human cells. Furthermore, these findings offer critical insights into the complex process of HPV16 and HPV18 integration and their potential contribution to the development of cervical cancer.
PCT No. PCT/UA94/00022 Sec. 371 Date Jan. 23, 1997 Sec. 102(e) Date Jan. 23, 1997 PCT Filed Aug. 12, 1994 PCT Pub. No. WO96/04943 PCT Pub. Date Feb. 22, 1996A BIOCOMPATIBLE HYDROGEL, is provided for use in the treatment of humans for cosmetic and functional defects (e.g. in mammas, vocal cords, penis, etc. as endoprostheses), in the provision of intratissue storage sites the prolonged-action medicinal preparations, in various applications as electroconductive immersion media, and in the life-long tamponing of caverns. It contains an acrylamide-based polymer produced in the presence of an initiator of radical polymerization in apyrogenic water as the dispersion medium. An increase in elasticity, shape retention capability, and stability of bulky implants, as well as corresponding therapeutic and cosmetic efficacy, mainly in the endoprosthetic applications is achieved due to the hydrogel containing cross-linked polyacrylamide produced by using a biocompatible cross-linking agent, such as methylene-bis-acrylamide, and preferably a mixture of ammonium persulfate and tetramethylethylenediamine as the initiator of polymerzation. A preferred concentration of the novel polymer in the hydrogel is from 3.5 to 9% by mass.
PURPOSE:To obtain a medicine, containing peptide compounds as an active ingredient and useful for preventing and treating Pneumocystis carinii infectious diseases. CONSTITUTION:A medicine is obtained by including a compound expressed by the formula (R<1> is H or acyl; R<2> is hydroxy or acyloxy; R<3> is H, hydroxy or hydroxysulfonyloxy; R<4> is H or carbamoyl; R<5> and R<6> are H, hydroxy, etc.) or its salts as an active ingredient. The aforementioned active ingredient can be prepared into a pharmaceutical in a dosage form such as a tablet, a pellet, a troche, a capsule, a suppository, a cream, an ointment, an aerosol, an inhalation powdery medicine, a solution, an emulsion or a suspension by blending normally used pharmaceutically permissible medicinal ingredients therewith according to a conventional method. The dose thereof is 0.01-100mg/kg/day compound expressed by the formula in the case of intravenous administration, 0.1-100mg/kg/day in the case of intramuscular administration and 0.5-100mg/kg/ day in the case of oral administration. The compound expressed by the formula is obtained by culturing a strain belonging to the genus Coleophoma in a nutrient culture medium.
Methods for protecting the brain and other tissues from virus-associated toxicity are provided. Patients are treated with a first immunizing virus prior to administration of a second, therapeutic cytolytic virus. The immunizing virus is preferably administered peripherally, and initiates an adaptive immune response that is sufficient to reduce or prevent the cytovirulence and inflammation caused by the therapeutic virus. The immunizing virus is administered one or more times, preferably at least twice, before administration of the therapeutic virus. The therapeutic virus can be the same virus as the immunizing virus, or a mutant or variant thereof. Preferably the therapeutic virus is an attenuated virus with reduced virulence compared to the immunizing virus.
This is a 48-week, open-label, single center pharmacist-run study to assess PrEP uptake and persistence among women at high-risk of HIV-1 acquisition in metro-Orlando at a community-based organization called Let's Beehive. All participants in the study will chose whether they want to start IM LA-CAB (with or without the oral lead-in) vs. daily oral TDF/FTC for PrEP. The study will include a Screening Phase (up to 56 days), and an open-label phase (Day 1 up to Week 48). Approximately 50 women defined as "high-risk" for HIV-1 infection who have a confirmed negative HIV test will be enrolled. All insured participants will be responsible for using their insurance plan to obtain coverage for their chosen PrEP medication, in addition to any labs required by the study. This expectation is clearly outlined in the informed consent. The study team will work with participants to minimize their co-pays for study medications and labs through the use of manufacturer and other external assistance programs. For participants who are under-or-uninsured, the study sponsor will provide financial coverage for approximately 20 participants (10 on LA-CAB and 10 on TDF/FTC) to receive PrEP medication and undergo study-required laboratory testing at no cost.
PURPOSE OF REVIEW: This year marks 10 years from the publication of the clinical consensus statement on pediatric chronic rhinosinusitis (CRS). Balloon sinuplasty did not meet criteria for consensus at that time because there was insufficient evidence on its efficacy and safety. The purpose of this review is to summarize the current evidence on balloon sinuplasty treatment for pediatric CRS.
RECENT FINDINGS: Balloon sinuplasty is not a cost-effective measure compared to adenoidectomy and endoscopic sinus surgery (ESS). In the pediatric population, benefits include short operative time, reduced tissue manipulation, and potential for decreased antibiotic courses. Alternatively, balloon dilation has increased equipment costs and there is a lack of robust prospective data that fully elucidates balloon sinuplasty's role in the management of pediatric CRS.
SUMMARY: Pediatric otolaryngologists should continue to perform first-line adenoidectomy and consider ESS based on imaging and other validated clinical scoring systems. Balloon sinuplasty has not yet been proven as an effective treatment for pediatric CRS and further large-scale investigations are required to overcome its lack of cost-effectiveness.
SCOPE: The rosehip (Rosa canina) is a perennial shrub with a reddish pseudofruit that has demonstrated antidiabetic, antiatherosclerotic, and antiobesogenic effects in rodent models but there is low information about the molecular mechanisms underlying these effects on the onset and progression of diet-induced obesity.
METHODS AND RESULTS: Four-week-old C57BL/6J male mice are subjected to a high-fat diet (HFD)-supplemented or not with R. canina flesh for 18 weeks. The results indicated that the R. canina flesh exerts a preventive effect on HFD-induced obesity with a significant reduction in body-weight gain and an improvement of hyperglycemia and insulin resistance caused by a HFD. At the tissue level, subcutaneous white adipose tissue exhibits a higher number of smaller adipocytes, with decreased lipogenesis. On its side, the liver shows a significant decrease in lipid droplet content and in the expression of genes related to lipogenesis, fatty acid oxidation, and glucose metabolism. Finally, the data suggest that most of these effects agree with the presence of a putative Perosxisome proliferator-activated receptor gamma (PPARγ) antagonist in the R. canina flesh.
CONCLUSIONS: R. canina flesh dietary supplementation slows down the steatotic effect of a HFD at least in part through the regulation of the transcriptional activity of PPARγ.
Compsns. for treating the effects of alcohol consumption contain as active ingredients (A) >=1 anion (opt. in salt form) derived from the tricarboxylic acid (Krebs) cycle or its immediate precursor; plus (C) an agent for protecting the stomach wall and/or (D) a choleretic agent. Pref. (A) are fructose, sorbose, sorbitol, mannitol or inositol and pref. (B) are acetate, malate or citrate incorporated as their alkali and/or alkaline earth salts. A typical (C) is dimethylpolysiloxane. The compsns. slow down absorption of alcohol by the stomach permitting its destruction by the intracellular enzymes of the gastrointestinal wall. They also stimulate hepatic metabolism of absorbed alcohol and excretion in the bile of toxic metabolites such as acetaldehyde. The compsns. are more effective than fructose of -ketoglutarate alone.
Stainless steel welders are exposed to heavy filler metals. We evaluated the concentration of these metals in whole blood and urine, and the relevant biochemical parameters in relation to the total chromosomal aberrations (CAs), chromatid-type (CTA-type, CTAs) and chromosome-type (CSA-type, CSAs), in 117 welders and control individuals. Statistically higher concentrations of the total Cr, Ni and Mn were observed in whole blood and urine of welders, and the concentrations were higher in welders who smoked. On the contrary, concentrations of urinary heavy metals Cr and Mn adjusted for creatinine were significantly higher in the control groups. A statistically higher frequency of total CAs was observed in the whole group of welders, and also in the non-smoking welders, as compared to controls. The frequency of total CAs significantly correlated with the concentration of Cr, Ni and Mn in whole blood (R=0.61, P˂0.0001, R=0.33, P˂0.0001 and R=0.66, P˂0.0001, respectively), with urinary concentrations of Ni and Mn (R=0.27, P=0.003 and R=0.28, P=0.003, respectively) and with urinary concentrations of Cr, Ni and Mn adjusted for creatinine (R=0.22, P=0.029, R=0.26, P=0.005 and R=0.20, P=0.030, respectively). Likewise, the frequency of CTA-types significantly correlated with the concentration of Cr and Mn in whole blood (R=0.31, P=0.0007 and R=0.34, P=0.0002). The frequency of CSA-types significantly correlated with concentrations of Cr, Ni and Mn in whole blood (R=0.43, P˂0.0001, R=0.38, P˂0.0001 and R=0.46, P˂0.0001, respectively). The statistically higher values of serum creatinine and total bilirubin were detected in all welders, as well as in smokers when compared to the corresponding controls. The exposure to heavy metals in welders increased the frequencies of CAs and altered the balance between urinary excretion of heavy metals and their possible accumulation.